Nuvalent, Inc.
NUVL
Kedudukan dalam Saham
#2114
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Harga Saham
$123.96
Disegerakkan terakhir: 2026-07-21
Modal Pasaran
$9.75B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
27.56%
Negara
US
Perdagangan Nuvalent, Inc. (NUVL)
Kategori
Healthcare
Bilangan saham terbitan bagi Nuvalent, Inc. (NUVL)
Bilangan saham terbitan setakat March 2026: 78.67M
Menurut laporan kewangan terkini dan harga saham Nuvalent, Inc., bilangan saham terbitan semasa ialah 78.67M. Pada akhir December 2023, syarikat mempunyai 58.22M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Nuvalent, Inc. (NUVL) dari 2019 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 78.67M | 18.46% |
| 2024 | 66.41M | 14.06% |
| 2023 | 58.22M | 17.22% |
| 2022 | 49.67M | 128.02% |
| 2021 | 21.78M | -4.73% |
| 2020 | 22.86M | -52.65% |
| 2019 | 48.28M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 222.74% |
US
|
|
| 396.00M | 403.37% |
US
|
|
| 478.91M | 508.76% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -20.95% |
NL
|
